angiotensinconvert
enzym
critic
involv
cardiovascular
physiolog
patholog
current
clinic
evalu
treat
acut
lung
failur
show
carboxypeptidas
deriv
paenibacillu
sp
enzym
decreas
angiotensin
ii
level
mice
protein
structur
analysi
homolog
share
structur
similar
mammalian
low
sequenc
ident
vitro
recombin
protein
catalyz
convers
angiotensin
ii
angiotensin
well
known
target
peptid
treatment
suppress
angiotensin
iiinduc
hypertens
cardiac
hypertrophi
fibrosi
mice
moreov
inhibit
pressur
overloadinduc
patholog
hypertrophi
myocardi
fibrosi
cardiac
dysfunct
mice
data
identifi
bacteri
carboxypeptidas
indic
evolut
shape
bacteri
carboxypeptidas
human
enzym
bacteri
engin
could
util
design
improv
protein
drug
hypertens
heart
failur
reninangiotensin
system
ra
essenti
role
maintain
blood
pressur
bp
homeostasi
well
fluid
salt
balanc
ra
activ
angiotensinconvert
enzym
ace
cleav
cterminu
decapeptid
angiotensin
ang
ang
gener
vasopressor
octapeptid
angiotensin
ii
ang
ii
ang
discov
human
homolog
ace
neg
regul
ra
catalyz
convers
ang
ii
angiotensin
ang
downregul
ang
ii
level
therebi
counterbalanc
ace
activ
physiolog
function
initi
identifi
regul
heart
function
bp
acer
fli
homolog
shown
essenti
heart
morphogenesi
cardiac
function
fli
although
activ
ra
gener
ang
ii
worsen
cardiovascular
patholog
cardiac
fibrosi
patholog
hypertrophi
heart
failur
enzymat
activ
exhibit
protect
role
cardiovascular
diseas
also
protect
role
improv
patholog
acut
respiratori
distress
syndrom
ard
acut
lung
injuri
diabet
nephropathi
ang
ii
overproduc
signal
enhanc
loss
detriment
lead
progress
cardiac
renal
pulmonari
patholog
treatment
recombin
human
protein
devoid
membraneanchor
domain
thu
solubl
demonstr
exhibit
benefici
effect
variou
anim
model
includ
heart
failur
acut
lung
injuri
diabet
nephropathi
forth
current
test
clinic
treat
ard
patient
despit
benefici
effect
glycosyl
protein
thu
prepar
requir
timeand
costconsum
protein
express
system
mammalian
insect
cell
may
advantag
drug
develop
medic
economi
ace
protein
belong
famili
zincbind
metallopeptidas
contain
hexxh
metalcoordin
motif
although
biolog
activ
two
enzym
differ
function
monocarboxypeptidas
wherea
ace
dipeptidylcarboxypeptidas
structur
analys
reveal
signific
homolog
ace
carboxypeptidas
hyperthermophil
archaeon
pfu
pyrococcu
furiosu
member
famili
carboxypeptidas
belong
famili
metallopeptidas
hexxh
activesit
motif
two
enzym
share
littl
amino
acid
sequenc
ident
yet
exhibit
similar
core
structur
activesit
region
addit
structur
similar
within
activesit
region
carboxypeptidas
bacterium
bacillu
subtili
report
suggest
function
might
conserv
previous
clone
daspartyl
endopeptidas
paenidas
paenibacillu
sp
new
substrain
b
subtili
paenidas
cleav
peptid
detect
alzheim
diseas
suggest
potenti
applic
therapeut
studi
show
paenibacillu
sp
carboxypeptidas
enzym
cleav
ang
ang
ii
ang
show
recombin
protein
downregul
ang
ii
level
mice
antagon
ang
iiinduc
hypertens
patholog
cardiac
hypertrophi
myocardi
fibrosi
also
show
benefici
effect
patholog
pressur
overloadinduc
heart
failur
mice
without
overt
toxic
identif
enzym
address
whether
protein
bacteria
first
search
publish
crystal
structur
carboxypeptidas
databas
merop
http
meropssangeracuk
found
three
microbi
carboxypeptidas
report
threedimension
structur
includ
bscap
bsucp
b
subtili
taq
thermu
aquaticu
pfu
p
furiosu
although
bscap
taq
pfu
show
low
sequenc
ident
examin
whether
bscap
taq
pfu
structur
similar
human
use
program
molecular
oper
environ
chemic
comput
group
canada
program
detect
bscap
protein
structur
relat
structur
protein
mostli
merg
fig
importantli
posit
key
amino
acid
constitut
catalyt
site
hisgluxxhi
motif
substratebind
region
almost
ident
protein
implic
bscap
may
similar
substrat
prefer
fig
supplementari
fig
supplementari
tabl
inde
previou
studi
bscap
structur
predict
may
structur
similar
bscap
search
bacteri
protein
exhibit
high
sequenc
ident
bscap
blast
found
bacap
carboxypeptidas
deriv
bacillu
amyloliquefacien
homolog
bscap
tabl
furthermor
found
recent
identifi
bacteri
strain
paenibacillu
sp
also
similar
carboxypeptidas
bscap
high
sequenc
ident
fig
supplementari
fig
supplementari
tabl
term
paenibacillu
sp
carboxypeptidas
hereaft
despit
evolut
distant
relationship
fig
bacteri
enzym
like
homolog
diverg
evolut
prepar
recombin
protein
bscap
bacap
escherichia
coli
protein
express
system
fig
protein
highli
express
solubl
e
coli
easili
purifi
anionexchang
gel
filtrat
chromatographi
supplementari
fig
inde
product
recombin
e
coli
mg
protein
yield
per
cultur
volum
l
effici
term
recov
protein
amount
compar
product
histag
insect
cell
mg
protein
yield
per
cultur
volum
l
moreov
time
cultur
purif
day
shorter
day
includ
baculoviru
prepar
supplementari
fig
first
test
whether
enzym
proteolyt
activ
hydrolyz
fluorogen
peptid
nmahisproli
dnp
previous
develop
specif
substrat
result
enzym
reveal
catalyz
hydrolysi
substrat
nmahisproli
dnp
fig
tabl
incub
ang
ii
peptid
bscap
bacap
vitro
enzym
convert
ang
ii
ang
fig
supplementari
fig
hand
depend
enzymat
activ
anion
cl
concentr
much
higher
bscap
bacap
fig
suggest
potent
activ
physiolog
condit
mammal
analysi
kinet
constant
fluorogen
substrat
reveal
potenc
protein
tabl
supplementari
fig
consist
ic
valu
inhibitor
human
almost
equival
tabl
supplementari
fig
addit
depend
proteolyt
activ
ph
temperatur
also
similar
supplementari
fig
e
moreov
variou
supplementari
fig
peptid
ang
angiotensin
ang
howev
cleav
ang
wherea
affect
ang
fig
g
tabl
consist
convert
ang
ang
fig
distinct
convers
ang
ang
address
convert
ang
ang
conduct
kinet
analysi
fig
j
supplementari
fig
ang
ang
ii
ang
peptid
detect
min
mix
ang
fig
ang
product
increas
final
reach
level
initi
ang
amount
wherea
ang
undetect
min
fig
j
hand
ang
ang
ii
exhibit
minor
peak
min
min
respect
peptid
becam
undetect
end
reaction
period
fig
consist
peptid
kinet
amino
acid
leucin
leu
histidin
phenylalanin
phe
gener
order
monocarboxyl
proteolysi
ang
ang
ang
ii
respect
fig
indic
convers
ang
ang
mediat
three
step
monocarboxyl
proteolysi
therefor
activ
convert
ang
ii
ang
peptid
ang
vitro
examin
effect
vivo
first
inject
mice
measur
plasma
enzymat
activ
indic
plasma
level
use
newli
fig
bacteriaderiv
carboxypeptidas
angiotensinconvert
enzym
like
enzym
crystal
structur
bscap
human
protein
inset
metalcoordin
residu
red
substratebind
residu
black
shown
b
phylogenet
tree
bacteri
carboxypeptidas
c
sdspage
analysi
recombin
protein
bscap
bacap
depend
proteolyt
activ
bscap
bacap
anion
concentr
activ
measur
hydrolysi
rate
fluorogen
substrat
nmahisproli
dnp
eh
hplc
analysi
angiotensin
peptid
ang
ii
e
ang
f
ang
g
ang
h
nmol
incub
vehicl
recombin
protein
recombin
protein
min
subject
hplc
analysi
j
kinet
analysi
hydrolysi
ang
hplc
analysi
angiotensin
peptid
gener
incub
ang
j
upper
panel
amino
acid
sampl
quantifi
lcm
system
j
lower
panel
experi
repeat
three
time
repres
chromatographi
chart
shown
j
valu
mean
sem
n
independ
experi
develop
substrat
nmaleuproli
dnp
h
intraperiton
ip
inject
mg
kg
ip
concentr
plasma
markedli
increas
peak
fig
plasma
level
gradual
decreas
almost
baselin
h
still
detect
plasma
h
fig
estim
initi
halflif
system
circul
h
almost
similar
h
next
examin
whether
treatment
affect
ang
iiinduc
elev
bp
first
measur
bp
carotid
arteri
anesthet
mice
use
transduc
cathet
fig
intraperiton
inject
ang
ii
mg
kg
ip
induc
acut
elev
arteri
bp
wildtyp
mice
wherea
pretreat
mg
kg
ip
significantli
suppress
ang
iiinduc
elev
arteri
pressur
fig
supplementari
fig
c
next
address
effect
hypertens
induc
chronic
ang
ii
treatment
although
continu
infus
ang
ii
osmot
minipump
elev
bp
measur
consciou
mice
daili
ip
inject
downregul
elev
bp
day
supplementari
fig
e
supplementari
fig
e
furthermor
test
whether
continu
infus
suppress
ang
iiinduc
hypertens
fig
infus
subcutan
use
osmot
minipump
detect
plasma
mice
day
supplementari
fig
b
although
report
immun
respons
associ
chronic
infus
result
degrad
observ
antibodi
detect
serum
mice
infus
week
supplementari
fig
implant
osmot
minipump
significantli
suppress
ang
iiinduc
hypertens
consciou
mice
fig
g
without
affect
heart
rate
fig
result
indic
antagon
vasopressor
effect
ang
ii
examin
effect
treatment
ang
ii
level
blood
acut
experi
ip
inject
ang
ii
fig
pretreat
markedli
downregul
massiv
increas
plasma
ang
ii
level
min
ang
ii
inject
fig
consist
chronic
experi
continu
infus
ang
ii
fig
continu
infus
addit
osmot
pump
significantli
decreas
ang
ii
level
plasma
day
fig
ang
known
exert
benefici
effect
cardiovascular
system
masang
receptor
also
measur
ang
level
plasma
mice
ang
level
plasma
significantli
upregul
acut
chronic
experiment
set
fig
l
hand
cotreat
ang
iiinject
mice
antagonist
masang
receptor
suppress
effect
ang
iiinduc
elev
bp
affect
fig
supplementari
fig
furthermor
cotreat
ang
ang
ii
downregul
ang
iiinduc
elev
bp
supplementari
fig
thu
hypotens
effect
primarili
mediat
downregul
ang
ii
level
chronic
infus
ang
ii
induc
cardiac
hypertrophi
fibrosi
examin
heart
mice
chronic
treat
highdos
ang
ii
mg
kg
per
day
without
mg
kg
per
day
week
suppress
ang
iiinduc
cardiac
hypertrophi
increas
heart
weight
hw
measur
hwtobodi
weight
ratio
hwbw
hw
tibia
length
hwtl
fig
c
supplementari
tabl
consist
ang
iiinduc
wall
thicken
heart
significantli
downregul
treatment
shown
echocardiographi
fig
e
supplementari
tabl
addit
mild
decreas
cardiac
contractil
ang
iiinfus
mice
prevent
treatment
determin
fraction
shorten
fs
fig
supplementari
tabl
moreov
significantli
prevent
ang
iiinduc
cardiac
fibrosi
fig
h
upregul
fibrot
gene
express
collagen
periostin
postn
fig
similar
result
obtain
daili
ip
inject
week
ang
iiinfus
mice
supplementari
fig
n
supplementari
tabl
result
demonstr
suppress
ang
iiinduc
hypertens
cardiac
hypertrophi
fibrosi
mitig
pressur
overloadinduc
heart
failur
treat
mice
pressur
overload
cardiac
stress
induc
transvers
aortic
constrict
tac
continu
infus
mg
kg
per
day
initi
immedi
tac
surgeri
fig
week
tac
hw
hwbw
hwtl
also
significantli
decreas
group
compar
vehicletr
control
fig
addit
pulmonari
congest
suppress
determin
lung
weight
bw
ratio
lwbw
lwtl
ratio
fig
f
echocardiographi
also
show
wall
thicken
significantli
downregul
treatment
fig
supplementari
tabl
addit
although
fs
significantli
decreas
vehicl
treatment
group
fs
preserv
mice
fig
similarli
treatment
significantli
suppress
increas
express
mrna
associ
cardiac
hypertrophi
anf
atrial
natriuret
factor
bnp
brain
natriuret
peptid
heavi
chain
tac
mice
fig
histolog
analysi
reveal
treatment
reduc
area
cardiac
fibrosi
interstiti
space
perivascular
region
heart
tac
mice
fig
b
consist
although
express
profibrot
gene
postn
increas
heart
vehicletr
mice
tac
markedli
downregul
express
profibrot
gene
fig
result
indic
exogen
treatment
protect
mice
pressur
overloadinduc
cardiac
dysfunct
hypertrophi
fibrosi
furthermor
examin
whether
potenti
toxic
effect
liver
kidney
serum
marker
liver
injuri
kidney
dysfunct
affect
measur
aspart
transaminas
ast
summari
cleavabl
peptid
indic
cleav
wherea
mean
cleav
hplc
analys
metabolit
peptid
treatment
shown
supplementari
fig
cleavabl
peptid
ref
alanin
transaminas
alt
blood
urea
nitrogen
bun
creatinin
cr
respect
fig
addit
decreas
bw
due
tac
heart
failur
prevent
treatment
supplementari
tabl
result
suggest
exhibit
overt
side
effect
mice
least
week
treatment
improv
establish
hypertens
heart
failur
determin
therapeut
effect
establish
diseas
first
examin
whether
treatment
improv
establish
hypertens
mice
receiv
ang
ii
infus
prior
treatment
fig
bp
elev
day
ang
ii
infus
daili
ip
inject
initi
fig
treatment
significantli
downregul
ang
iiinduc
increas
bp
level
vehicletr
control
mice
fig
thu
amelior
establish
hypertens
next
investig
effect
establish
cardiac
dysfunct
week
tac
surgeri
mice
background
exhibit
cardiac
dysfunct
signific
decreas
fs
fig
g
osmot
minipump
contain
vehicl
implant
time
point
mg
kg
per
day
infus
week
treatment
significantli
increas
fs
compar
vehicletr
mice
mice
treatment
fig
tabl
indic
improv
cardiac
dysfunct
addit
cardiac
hypertrophi
significantli
suppress
treatment
fig
pulmonari
congest
also
improv
fig
l
consist
treatment
significantli
downregul
increas
express
mrna
associ
patholog
cardiac
hypertrophi
bnp
fibrosi
postn
fig
furthermor
challeng
sever
cardiac
dysfunct
mice
tac
mice
exhibit
profound
declin
cardiac
contractil
week
tac
fig
supplementari
fig
treatment
start
week
tac
markedli
suppress
progress
heart
failur
mice
supplementari
fig
studi
elucid
bacteriaderiv
carboxypeptidas
enzymat
activ
show
cleav
ang
ii
ang
ang
downregul
ang
ii
level
mice
demonstr
ang
iiinduc
hypertens
cardiac
hypertrophi
fibrosi
suppress
treatment
show
improv
cardiac
dysfunct
hypertrophi
fibrosi
induc
pressur
overload
mice
among
three
bacteri
carboxypeptidas
test
show
depend
proteolyt
activ
anion
concentr
characterist
activ
also
show
ph
optimum
equival
addit
ic
also
equival
although
exhibit
quit
similar
proteolyt
activ
seem
differ
substrat
specif
two
enzym
like
broad
specif
proteolyt
effect
peptid
convert
ang
ang
ang
wherea
cleav
ang
superimposit
bscap
structur
indic
posit
substratebind
amino
acid
residu
metalbind
residu
match
although
substrat
nmahisproli
dnp
cleav
potenc
found
nmaleuproli
dnp
catalyz
specif
shown
suggest
hydrophob
differ
substrat
specif
elucid
ongo
analysi
crystal
structur
although
hypotens
action
mediat
mainli
ang
ii
downregul
mg
kg
per
day
exhibit
potent
therapeut
effect
tacinduc
heart
failur
ang
iiinduc
heart
failur
eg
inhibit
cardiac
hypertrophi
hwbw
increas
tabl
g
h
histolog
heart
masson
trichrom
stain
g
bar
indic
mm
upper
panel
lower
panel
respect
quantif
fibrosi
heart
h
mice
treat
vehicl
vehicl
n
vehicl
n
ang
ii
vehicl
n
ang
ii
n
ik
qrtpcr
analysi
profibrot
gene
express
heart
mice
treat
vehicl
vehicl
n
vehicl
n
ang
ii
vehicl
n
ang
ii
n
mrna
level
collagen
f
periostin
postn
g
h
normal
gapdh
valu
mean
sem
bf
hk
twoway
anova
sidak
multiplecomparison
test
number
squar
bracket
show
signific
pvalu
tac
model
vs
inhibit
ang
iiinfus
model
hand
previou
studi
show
similar
antihypertroph
effect
tac
ang
iiinfus
model
differ
may
explain
slight
differ
substrat
specif
although
convert
ang
ang
ineffici
requir
ace
convers
ang
ang
target
ang
ang
ang
ii
peptid
monocarboxypeptidas
thu
convers
ang
ang
ii
ang
may
contribut
effici
downmodul
ra
tac
heart
failur
addit
ang
vasoprotect
peptid
act
cognat
ma
receptor
also
antifibrot
cardioprotect
function
heart
failur
thu
degrad
ang
ang
would
benefici
enhanc
ang
gener
treat
fail
heart
furthermor
target
biolog
peptid
angiotensin
peptid
subtl
differ
substrat
specif
may
licens
degrad
peptid
differ
manner
even
new
peptid
substrat
differ
target
addit
current
use
drug
inhibit
ang
ii
gener
signal
ace
inhibitor
angiotensin
receptor
blocker
direct
downmodul
ang
ii
level
protein
one
promis
candid
new
therapeut
strategi
cardiovascular
diseas
ang
iirel
diseas
eg
ard
hand
although
mass
product
protein
drug
cost
due
requir
mammalian
cell
express
system
easili
prepar
e
coli
express
system
cost
effect
therapeut
efficaci
less
toxic
mous
heart
failur
model
would
warrant
investig
microbi
carboxypeptidas
diseas
model
furthermor
human
enzym
bacteria
might
pave
way
new
strategi
engin
evolut
bacteri
protein
better
design
prepar
recombin
protein
drug
search
bacteriaderiv
enzym
sequenc
comparison
perform
use
blast
merop
http
meropssangeracuk
tool
avail
onlin
similar
search
superposit
structur
protein
perform
molecular
oper
environ
moe
chemic
comput
group
inc
montreal
qc
canada
multipl
sequenc
align
enzym
sequenc
perform
use
clustalw
tool
avail
onlin
phylogenet
tree
draw
perform
use
njplot
program
http
douaprabi
frsoftwarenjplot
fig
therapeut
effect
establish
hypertens
cardiac
dysfunct
ae
therapeut
effect
establish
hypertens
experiment
protocol
ang
ii
infus
mgkgday
initi
day
treatment
mice
inject
mgkg
ip
vehicl
twice
day
blood
pressur
measur
tailcuff
system
h
inject
systol
b
diastol
c
mean
bp
heart
rate
e
mice
treat
ang
ii
vehicl
n
ang
ii
n
vehicl
vehicl
n
fl
therapeut
effect
establish
cardiac
dysfunct
experiment
protocol
f
mice
tac
surgeri
week
treatment
mgkgday
vehicl
continu
infus
osmot
minipump
echocardiographi
paramet
fraction
shorten
fs
g
mice
treat
sham
vehicl
n
tac
vehicl
n
tac
n
repres
photograph
heart
mice
tac
h
bar
indic
mm
hwbw
hwtl
j
lwbw
k
lwtl
l
mice
treat
sham
vehicl
n
tac
vehicl
n
tac
n
mq
qrtpcr
analysi
express
heart
failur
gene
profibrosi
gene
heart
n
mice
per
group
valu
mean
sem
twoway
anova
sidak
multiplecomparison
test
g
oneway
anova
sidak
multiplecomparison
test
comparison
group
twotail
pair
ttest
treatment
group
iq
oneway
anova
sidak
multiplecomparison
test
number
next
squar
bracket
show
signific
pvalu
multipl
infect
moi
pfucel
cultur
ii
serumfre
medium
invitrogen
use
ml
shaker
flask
rpm
h
purifi
profin
imac
nicharg
resin
biorad
elut
mm
imidazol
dialyz
phosphatebuff
salin
pb
vitro
activ
measur
determin
kinet
constant
k
k
cat
valu
recombin
human
calbiochem
use
nmahisproli
dnp
substrat
determin
michaelismenten
model
use
graphpad
prism
version
la
jolla
ca
usa
lcm
quantif
amino
acid
leu
phe
sampl
dilut
perchlor
acid
centrifug
g
min
aliquot
inject
shimadzu
lcm
system
kyoto
japan
equip
electrospray
ion
sourc
nebul
ga
mice
assign
stratifi
random
base
bw
therapeut
experi
fig
supplementari
fig
mice
assign
stratifi
random
base
systol
bp
experi
ang
iiinduc
hypertens
fig
fs
experi
tacinduc
cardiac
dysfunct
fig
supplementari
fig
treatment
measur
perform
use
doubleblind
method
invas
measur
arteri
blood
pressur
acut
hemodynam
experi
perform
male
mice
nineti
minut
hemodynam
measur
mice
pretreat
ip
inject
either
mg
kg
ip
steril
pb
vehicl
mice
anesthet
isofluran
bodi
temperatur
maintain
use
heat
pad
throughout
experi
mous
secur
restrain
supin
posit
mechan
ventil
tracheal
cannul
peak
inflat
pressur
cm
h
breath
min
ventelit
harvard
apparatu
taper
cathet
fill
heparin
salin
unit
ml
insert
right
carotid
arteri
record
arteri
bp
via
pressur
transduc
min
stabil
period
systol
diastol
mean
bp
obtain
power
lab
data
acquisit
system
ad
instrument
heart
rate
calcul
use
softwar
ad
instrument
min
vehicl
inject
ang
ii
mg
kg
ip
vehicl
inject
chang
bp
analyz
subsequ
min
time
period
transvers
aortic
constrict
tenweekold
male
mice
subject
pressur
overload
tac
one
therapeut
experi
fig
mice
use
surgic
tac
procedur
result
sever
dysfunct
mous
strain
briefli
mice
anesthet
via
ip
inject
ketamin
mg
kg
xylazin
mg
kg
longitudin
incis
made
proxim
portion
sternum
aortic
arch
ligat
overli
needl
silk
needl
immedi
remov
leav
discret
region
constrict
shamtreat
group
underw
similar
procedur
without
ligat
echocardiographi
perform
indic
time
point
tac
sham
surgeri
mice
kill
cervic
disloc
echocardiographi
blood
pressur
measur
echocardiograph
measur
perform
previous
describ
briefli
consciou
mice
gentli
grab
hand
held
apparatu
echocardiographi
perform
use
equip
mhz
linear
transduc
visual
sonic
fs
calcul
follow
fs
lvedd
lvesd
lvedd
mmode
imag
obtain
measur
wall
thick
chamber
dimens
use
leadingedg
convent
adapt
american
societi
echocardiographi
bp
measur
consciou
mice
warm
min
measur
measur
bp
measur
programm
sphygmomanomet
softron
japan
use
tailcuff
method
day
daili
train
pharmacolog
intervent
treat
mice
examin
two
rout
administr
daili
ip
inject
subcutan
continu
infus
osmot
minipump
alzet
model
alza
corp
dosag
rout
ang
ii
sigmaaldrich
treatment
experi
describ
figur
legend
prevent
experi
treatment
initi
time
implant
ang
iifil
osmot
minipump
complet
tac
surgeri
coinfus
ang
ii
subcutan
mice
week
fig
fig
ang
ii
load
individu
pump
mice
implant
two
pump
ang
ii
infus
week
supplementari
fig
ang
iifil
osmot
minipump
alzet
model
replac
new
one
week
implant
two
week
treatment
bp
measur
echocardiographi
perform
chronic
experi
ip
inject
bp
measur
h
ip
inject
supplementari
fig
therapeut
experi
fig
supplementari
fig
treatment
initi
establish
hypertens
pressur
overloadinduc
cardiac
dysfunct
examin
effect
hypotens
action
fig
supplementari
fig
consciou
mice
preinject
mg
kg
ip
vehicl
min
measur
inject
ang
ii
mg
kg
ip
mg
kg
ip
combin
baselin
data
bp
obtain
bp
measur
everi
min
inject
tailcuff
method
histolog
heart
tissu
fix
formalin
embed
paraffin
section
prepar
stain
hematoxylin
eosin
masson
trichrom
stain
measur
cardiac
fibrosi
area
highresolut
imag
magnif
heart
section
stain
masson
trichrom
taken
use
biorevo
microscop
keyenc
fibrosi
area
quantifi
use
imagepro
softwar
media
cybernet
quantit
realtim
pcr
rna
extract
use
trizol
reagent
invitrogen
cdna
synthes
use
primescript
rt
reagent
kit
takara
sequenc
forward
revers
primer
gene
studi
shown
supplementari
tabl
realtim
pcr
run
plate
use
sybr
premix
extaq
ii
takara
accord
instruct
manufactur
rel
gene
express
level
quantifi
use
thermal
cycler
dice
real
time
system
ii
softwar
takara
measur
ang
ii
ang
mous
plasma
plasma
ang
ii
ang
level
measur
enzymelink
immunosorb
assay
elisa
peptid
extract
blood
sampl
collect
tube
contain
ethylenediamin
tetraacet
acid
mm
ophenanthrolin
mm
pepstatin
mm
phydroxymercuribenzo
acid
mm
centrifug
g
min
plasma
save
store
process
angiotensin
peptid
acidifi
subject
solidphas
extract
use
seppak
cartridg
water
quantiti
ang
ii
peptid
extract
determin
use
elisa
kit
enzo
life
scienc
plasma
ang
concentr
also
determin
subject
peptid
extract
measur
ang
elisa
kit
cusabio
biotech
measur
liver
kidney
function
plasma
level
ast
alt
bun
cr
measur
marker
liver
kidney
damag
respect
use
fuji
drichem
slide
kit
fujifilm
corpor
statist
analys
data
present
mean
valu
sem
statist
signific
two
experiment
group
determin
use
student
twotail
ttest
comparison
paramet
among
three
group
analyz
oneway
analysi
varianc
anova
follow
sidak
multiplecomparison
test
comparison
done
group
two
factor
level
twoway
anova
sidak
multiplecomparison
test
use
p
consid
signific
power
analysi
perform
result
initi
anim
experi
statist
softwar
r
valu
cohen
f
calcul
betweengroup
varianc
withinsubgroup
varianc
effect
size
experi
data
calcul
p
power
minim
number
anim
determin
report
summari
inform
research
design
avail
natur
research
report
summari
link
articl
data
support
find
studi
avail
correspond
author
upon
reason
request
sourc
data
use
gener
fig
